Is Elanco Animal Health Incorporated (ELAN) a Buy, Sell, or Hold?
NYSE : ELAN
Elanco Animal Health Incorporated
$26.39 USD
-$0.07 (-0.26%)
- Volume
- 5.19M
- Average Volume
- 5.83M
- Market Capitalization
- $13.18B
- P/E Ratio
- -53.01
- Dividend Yield
- 0.00%
- Price Target
- $29.00
- Year High
- $27.72
- Year Low
- $13.39
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.16
Company Overview
NYSE
Jeffrey N. Simmons
Drug Manufacturers - Specialty & Generic
Healthcare
ELAN
9900
US
USD
Liquidity Metrics
0.61
2.16
1.12
0.26
0.00
Sales & Valuation
$4.72B
2.69
2.02
41.84
0.63
Profitability
-$0.47
-$232M
-4.95%
-4.03%
-3.64%
-1.83%
P/E Metrics
-53.01
0.34
0.34
Analyst Price Target & Rating
$29.00
$30.00
$26.00
1/5
21 Analysts
-9.00%
Financial Health Scores
1.51
5/9
$1.92B
$13.22B
$6.72B
$73M
Key Metrics (TTM)
$16.74B
3.42
21.92
2.16
-3.64%
3.77%
-1.84%
2.39%
285 days
Company Executives
| Name | Title |
|---|---|
| Ellen de Brabander | Executive Vice President of Research, Development & Regulatory Affairs |
| Jeffrey N. Simmons | President, Chief Executive Officer & Director |
| Ramiro Martin Cabral | Executive Vice President & President of Elanco International |
| Timothy J. Bettington | Executive Vice President of Center of Strategic Growth |
| David S. Kinard | Executive Vice President of Human Resources, Corporate Communications & Administration |
| James Meer | Senior Vice President & Chief Accounting Officer |
| Larbi Van Lier | Senior Vice President of Asia |
| Robert VanHimbergen | Executive Vice President & Chief Financial Officer |
| Shiv O'Neill | Executive Vice President, General Counsel & Corporate Secretary |
| Tiffany Ann Kanaga | Vice President of Investor Relations & ESG |
Poll Results
No votes yet today — be the first to share your view!
About Elanco Animal Health Incorporated (NYSE:ELAN) Stock
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aqu ... aculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
2026-07-31 07:32:00
Report highlights Elanco's impact through innovation, expanded access to animal care, a stronger and more sustainable food system and investment in people and communities INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today released its 2025 Impact Report, "Leading with Purpose," highlighting how the company brings together purpose, innovation and business strategy to help address some of society's most pressing challenges. The report details Elanco's progress across four interconnected areas: going beyond for animals, customers, society and its people.
Elanco Animal Health Inc (ELAN) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 66/100
2026-07-29 20:23:00
On July 29, 2026, Elanco Animal Health Inc (ELAN) shares rose 3.4% to $26.39, continuing a positive trend in the stock's price performance. Over the past year,
Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: Should You Buy?
2026-07-29 11:06:13
Elanco Animal Health (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2026-07-23 03:42:01
California Public Employees Retirement System cut its stake in shares of Elanco Animal Health Incorporated (NYSE: ELAN) by 4.1% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 830,209 shares of the company's stock after selling 35,888 shares during the period. California Public
2026-07-22 13:02:10
Does Elanco Animal Health Incorporated (ELAN) have what it takes to be a top stock pick for momentum investors? Let's find out.
2026-07-22 06:27:00
Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro: Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours of treatment.i Kills the lone star tick (Amblyomma americanum) within 12 hours of infestation; achieving the fastest3 initial speed of tick kill compared to the competition.ii Achieves a rapid speed of kill4 on Day 0 and on Day 28, with no statistically significant drop-off in performance at the end of the dosing period.i,ii Outlasts competitors whose speed of kill2,4 performance declined at the end of the month.i,ii INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- When it comes to killing ticks, veterinarians and pet owners want it done fast. New data published in Parasites & Vectors, a leading peer-reviewed publication, demonstrates that Elanco Animal Health's (NYSE: ELAN) Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) kills ticks1 faster2 than leading competitors Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets).i Newly Published Data Found Credelio Quattro: Faster 2 Tick 1 Speed of Kill: Credelio Quattro is the only product proven to significantly reduce black-legged ticks within 8 hours.i Lotilaner, the active ingredient in Credelio Quattro also has the fastest initial tick speed of kill against the lone star tick - in just 12 hours – and sustains the advantage throughout the dosing interval.ii Outperforms the Competition: Outperforms Simparica Trio® (12 hours) and NexGard® Plus (24 hours) at the end of the dosing period (Day 28).i Consistency Over Competitors: Achieves 8-hour speed of kill1 on Day 0 and on Day 28 with no performance drop-off.
2026-07-18 03:11:13
Allspring Global Investments Holdings LLC acquired a new position in Elanco Animal Health Incorporated (NYSE: ELAN) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,871,561 shares of the company's stock, valued at approximately $66,390,000. Allspring Global Investments Holdings LLC owned 0.58%
Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?
2026-07-15 13:10:25
Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Frequently Asked Questions
-
What is the current Elanco Animal Health Incorporated (ELAN) stock price?
-
Elanco Animal Health Incorporated(NYSE:ELAN) stock price is $26.39 in the last trading session. During the trading session, ELAN stock reached the peak price of $27.72 while $13.39 was the lowest point it dropped to. The percentage change in ELAN stock occurred in the recent session was --0.26% while the dollar amount for the price change in ELAN stock was -$0.07.
-
ELAN's industry and sector of operation?
-
The NYSE listed ELAN is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of ELAN?
-
Ellen de Brabander | Executive Vice President of Research, Development & Regulatory Affairs
Jeffrey N. Simmons | President, Chief Executive Officer & Director
Ramiro Martin Cabral | Executive Vice President & President of Elanco International
Timothy J. Bettington | Executive Vice President of Center of Strategic Growth
David S. Kinard | Executive Vice President of Human Resources, Corporate Communications & Administration -
How many employees does ELAN have?
-
Number of ELAN employees currently stands at 9900. ELAN operates from 450 Elanco Circle, Indianapolis, IN 46221, US.
-
Link for ELAN official website?
-
Official Website of ELAN is: https://www.elanco.com
-
How do I contact ELAN?
-
ELAN could be contacted at phone #877 352 6261 and can also be accessed through its website. ELAN operates from 450 Elanco Circle, Indianapolis, IN 46221, US.
-
How many shares of ELAN are traded daily?
-
The average number of ELAN shares traded daily for last 3 months was 5.83M.
-
What is the market cap of ELAN currently?
-
The market value of ELAN currently stands at $13.18B with its latest stock price at $26.39